Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | XBP1 | P17861 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.41 |
| ▸ | CES2 | O00748 | 3/20 | 0.40 |
| ▸ | CES1 | P23141 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | DAO | P14920 | 1/20 | 0.40 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19967067 | 0.80 | MAPT (0.40) | NPSR1LMNAMAPTXBP1ATM | |
| SCHEMBL587894 | 0.80 | ALDH1A1 (0.43) | NPSR1LMNAMAPTXBP1ATM | |
| SCHEMBL27236822 | 0.80 | CA1 (0.47) | MAPTALDH1A1KMT2A | |
| SCHEMBL1003233 | 0.78 | TSHR (0.44) | NPSR1LMNAMAPTXBP1ATM | |
| SCHEMBL27236892 | 0.77 | NAPRT (0.43) | LMNAPTGS2NAPRTALDH1A1KMT2A | |
| SCHEMBL26956166 | 0.77 | CES2 (0.44) | NPSR1LMNAMAPTCES2CES1 | |
| SCHEMBL28800940 | 0.76 | TSHR (0.42) | NPSR1LMNAMAPTXBP1ATM | |
| SCHEMBL27597544 | 0.76 | TSHR (0.42) | NPSR1LMNAMAPTXBP1ATM | |
| SCHEMBL28163178 | 0.76 | CES1 (0.40) | NPSR1LMNAMAPTXBP1ATM | |
| SCHEMBL1653521 | 0.76 | CA2 (0.42) | NPSR1MAPTCES2CES1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102260200-B | Method for synthesizing phenylsulfone compounds | UNIV TSINGHUA | 2013-08-14 | — | — | CN | disclosed |
| CN-102260200-A | Method for synthesizing phenylsulfone compounds | — | 2011-11-30 | — | — | CN | disclosed |
| US-20100228015-A1 | PRODRUG DERIVATIVES OF ACIDS USING ALCOHOLS WITH HOMOTOPIC HYDROXY GROUPS AND METHODS FOR THEIR PREPARATION AND USE | DELONG MITCHELL A | 2010-09-09 | — | — | US | disclosed |
| EP-1020445-B1 | FUSED PYRIDINE DERIVATIVES | EISAI R&D MAN CO LTD (JP) | 2008-08-13 | — | — | EP | disclosed |
| US-20070254920-A1 | Prodrug derivatives of acids using alcohols with homotopic hydroxy groups and methods for their preparation and use | AERIE PHARMACEUTICALS, INC. (US) | 2007-11-01 | — | — | US | disclosed |
| US-6875761-B2 | Certain 1,3-disubstituted isoquinoline derivatives | EISAI CO., LTD. (JP) | 2005-04-05 | — | — | US | disclosed |
| US-20040204421-A1 | Certain 1,3-disubstituted isoquinoline derivatives | EISAI CO., LTD. | 2004-10-14 | — | — | US | disclosed |
| US-6790844-B2 | MUSCLE RELAXANTS; ANTISEROTONINE AGENT | EISAI CO., LTD (JP) | 2004-09-14 | — | — | US | disclosed |
| US-20020013460-A1 | Condensed pyridine compound | EISAI CO., LTD | 2002-01-31 | — | — | US | disclosed |
| US-6340759-B1 | ANTISPASMODIC AGENTS | EISAI CO., LTD. (JP) | 2002-01-22 | — | — | US | disclosed |
| EP-1020445-A1 | FUSED PYRIDINE DERIVATIVES | Eisai Co., Ltd. (JP) | 2000-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013460-A1 | Condensed pyridine compound | MUSK, HTR1A, PAX3 | NPSR1 1494/4885LMNA 1057/4885MAPT 1892/4885 |
| US-20070254920-A1 | Prodrug derivatives of acids using alcohols with homotopic hydroxy groups and methods for their preparation and use | HCAR1, HCAR2, PAICS | NPSR1 1344/4885LMNA 3188/4885MAPT 3694/4885 |
| US-20040204421-A1 | Certain 1,3-disubstituted isoquinoline derivatives | MUSK, HTR1A, RYR1 | NPSR1 1759/4885LMNA 1917/4885MAPT 3756/4885 |
| US-20100228015-A1 | PRODRUG DERIVATIVES OF ACIDS USING ALCOHOLS WITH HOMOTOPIC HYDROXY GROUPS AND METHODS FOR THEIR PREPARATION AND USE | HCAR1, HCAR2, PAICS | NPSR1 1344/4885LMNA 3188/4885MAPT 3694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.